I now have comprehensive data from multiple authoritative textbooks. Let me compile the full answer.
HELLP Syndrome
Definition & Acronym
HELLP is an acronym for:
- H - Hemolysis (microangiopathic hemolytic anemia)
- EL - Elevated Liver enzymes
- LP - Low Platelets
It represents a severe form of preeclampsia in which hepatic and hematologic abnormalities dominate, driven by thrombotic microangiopathy (TMA).
- Harrison's Principles of Internal Medicine 22E, p. 2490
- Comprehensive Clinical Nephrology 7e, p. 630
- Brenner and Rector's The Kidney, p. 2028
Epidemiology
| Statistic | Figure |
|---|
| Incidence in all pregnancies | 0.2-0.9% |
| In severe preeclampsia | 10-20% |
| Maternal mortality | 1-7.4% (up to 34% in severe cases) |
| Perinatal mortality | 7-34% (depends on gestational age) |
| Cases before week 28 | ~20% |
| Postpartum onset | ~30% of cases |
Risk factors: Advanced maternal age, Caucasian ethnicity, multiparity, abnormal placentation, family history, elevated fetal mRNA for FLT1/endoglin. Patients with antiphospholipid syndrome have elevated risk.
Importantly, ~20% of cases have NO preceding hypertension or proteinuria, making it a diagnostic trap.
Pathophysiology
The exact cause is unknown, but the central mechanism involves:
- Abnormal placentation → systemic endothelial dysfunction
- Activation of the coagulation cascade → fibrin deposition in hepatic sinusoids and microvasculature
- Microangiopathic hemolytic anemia → platelet consumption and red cell fragmentation (schistocytes)
- Hepatic ischemia → from sinusoidal fibrin deposition and intravascular hypovolemia → elevated transaminases
- Complement dysregulation - complement gene mutations or dysfunction found in 30-40% of HELLP patients
- Elevated inflammatory markers (CRP, IL-1Ra, IL-6) and soluble HLA-DR compared to preeclampsia alone
Clinical Features
| Symptom/Sign | Notes |
|---|
| Epigastric / RUQ pain | Most common presenting symptom - can mimic gastroenteritis, cholecystitis, pancreatitis |
| Nausea & vomiting | Frequent accompanying feature |
| Malaise | May mimic viral syndrome |
| Headache, blurred vision | Signs of CNS involvement |
| Hypertension | May be absent initially or at all |
| Proteinuria | Present in 86-100% overall, but may be absent |
Key pitfall: Hypertension may be absent, leading to misdiagnosis as gastroenteritis, cholecystitis, hepatitis, or pyelonephritis. Any pregnant woman at >20 weeks gestation (or up to 7 days postpartum) with abdominal pain must be evaluated for HELLP.
- Tintinalli's Emergency Medicine, p. 674
Diagnostic Criteria
ACOG Task Force Criteria (current standard)
- Hemolysis PLUS at least 2 of the following:
- Thrombocytopenia (platelets <100,000/μL)
- Renal insufficiency (creatinine >1.1 mg/dL or doubling)
- Impaired liver function (transaminases twice upper limit of normal)
- Pulmonary edema
- New-onset headache unresponsive to medication, or visual symptoms
Key Lab Findings
| Test | Finding in HELLP |
|---|
| Peripheral smear | Schistocytes (fragmented RBCs) |
| Platelet count | <100,000/μL (<150,000 suspicious) |
| LDH | >600 U/L |
| AST/ALT | Elevated (usually <500 U/L, rarely up to >1000 U/L) |
| Total bilirubin | >1.2 mg/dL |
| Serum haptoglobin | Low (hemolysis marker) |
| Urine protein | Proteinuria (86-100%) |
Classification Systems
Mississippi Triple-Class System (platelet-based severity)
| Class | Platelet Nadir |
|---|
| Class I (Severe) | ≤50,000/mm³ |
| Class II (Moderate) | 50,001-100,000/mm³ |
| Class III (Mild) | 100,001-150,000/mm³ |
Tennessee Classification
-
Complete HELLP: All 3 criteria present (hemolysis + elevated LDH/AST + platelets <100,000)
-
Incomplete (Partial) HELLP: Only 1 or 2 criteria present (e.g., EL only, LP only, HEL without thrombocytopenia)
-
Sleisenger & Fordtran's GI and Liver Disease, p. 4067
-
Yamada's Textbook of Gastroenterology 7e
Complications
Maternal
| Complication | Approximate Rate |
|---|
| Eclampsia | 6% |
| Placental abruption | 10% |
| DIC | 8-21% |
| Acute renal failure | 5-50% |
| Pulmonary edema | 10% |
| Hepatic subcapsular hematoma/rupture | ~1% of HELLP cases |
| Cerebral infarction/hemorrhage | Rare but life-threatening |
| Purtscher-like retinopathy | Rare (hemorrhagic/vaso-occlusive) |
Liver rupture occurs predominantly in the right lobe, following subcapsular hemorrhage stretching the hepatic capsule. More than 95% of liver ruptures in pregnancy involve severe preeclampsia/HELLP. The triad of RUQ pain + hypertension + shock should raise immediate suspicion.
Fetal
- Preterm birth
- IUGR (fetal growth restriction)
- Fetal demise
Differential Diagnosis
The table below summarizes the key distinctions from overlapping conditions:
| Feature | HUS/TTP | HELLP | AFLP |
|---|
| Hemolytic anemia | +++ | ++ | ± |
| Thrombocytopenia | +++ | ++ | ± |
| Coagulopathy | - | ± | + |
| CNS symptoms | ++ | ± | ± |
| Renal failure | +++ | + | ++ |
| Hypertension | ± | +++ | ± |
| Elevated AST | ± | ++ | +++ |
| Elevated bilirubin | ++ | + | +++ |
| Serum ammonia | Normal | Normal | High |
| Effect of delivery | None | Recovery | Recovery |
| ADAMTS13 | <10% (TTP) | 30-60% reduced | Normal |
| Management | Plasma exchange | Supportive + delivery | Supportive + delivery |
LDH:AST ratio can help: ratio ~13:1 in HELLP with preeclampsia vs. ~29:1 in non-preeclamptic patients.
- Brenner and Rector's The Kidney, p. 2034-2036
- Harrison's 22E
Management
1. Immediate Stabilization
- IV access, blood products on standby
- Continuous fetal monitoring
- Seizure prophylaxis: Magnesium sulfate (4 g IV loading dose, then 1-2 g/hr infusion)
- Antihypertensives for BP ≥160/110 mmHg:
| Drug | Mechanism | Onset | Dosage |
|---|
| Labetalol | α + β blocker | 5 min | 20 mg IV, then 40-80 mg q10 min (max 300 mg) |
| Hydralazine | Arterial vasodilator | 20 min | 5 mg IV or 10 mg IM, repeat q20 min |
| Nifedipine | Calcium channel blocker | 10-20 min | 10 mg PO, repeat in 30 min |
2. Delivery - The Definitive Treatment
- The key treatment is delivery; HELLP syndrome resolves spontaneously after delivery
- Gestational age ≥34 weeks: Prompt delivery recommended
- <34 weeks, no serious complications: Consider antenatal corticosteroids (betamethasone) for fetal lung maturity FIRST, then deliver
- Serious maternal/fetal complications: Prompt delivery regardless of gestational age
- Cesarean section: Consider platelet transfusion to 40,000-50,000 cells/μL before procedure
3. Platelet Transfusion
- Indicated for platelets <40,000-50,000/μL, especially pre-operatively
4. Corticosteroids (controversial)
- Dexamethasone IV has been used in some protocols to accelerate recovery of platelets and transaminases, especially postpartum - but evidence is mixed and this is NOT routinely recommended per some guidelines
5. Plasma Exchange
- No proven benefit in HELLP
- May be indicated if TTP has not been ruled out
- Eculizumab (anti-C5 complement inhibitor) has been reported in small case series if complement-mediated aHUS is suspected
6. Postpartum Monitoring
- Labs may worsen before improving after delivery
- Resolution typically within 48-72 hours, complete by 5 days
- Monitor up to 7 days postpartum since 20-30% develop HELLP after delivery
Prognosis & Recurrence
- Maternal mortality: ~1% (with modern care), perinatal mortality 7-34%
- HELLP usually resolves fully after delivery
- Recurrence risk in future pregnancies: reported at ~3-27%
- Patients with complement mutations (30-40% of HELLP) may be at elevated risk of aHUS in future pregnancies
Summary Mnemonic
HELLP = Think whenever a pregnant woman >20 weeks presents with:
- Headache + Epigastric pain + Low platelets + Liver enzymes up + Proteinuria
Sources: Harrison's Principles of Internal Medicine 22E | Brenner & Rector's The Kidney | Tintinalli's Emergency Medicine | Sleisenger & Fordtran's GI and Liver Disease | Yamada's Textbook of Gastroenterology 7e | Comprehensive Clinical Nephrology 7e | Creasy & Resnik's Maternal-Fetal Medicine | Textbook of Family Medicine 9e